|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
European Association For The Study Of The
Liver1; European Organisation For Research And Treatment Of Cancer,
. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan X, Cui L, Zeng Y, Song W, Gaur U and
Yang M: 14-3-3 proteins are on the crossroads of cancer, aging, and
age-related neurodegenerative disease. Int J Mol Sci. 20(pii):
E35182019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sluchanko NN and Gusev NB: Moonlighting
chaperone-like activity of the universal regulatory 14-3-3
proteins. FEBS J. 284:1279–1295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Heusden GP: 14-3-3 proteins:
Regulators of numerous eukaryotic proteins. IUBMB Life. 57:623–629.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yaffe MB: How do 14-3-3 proteins
work?-Gatekeeper phosphorylation and the molecular anvil
hypothesis. FEBS Lett. 513:53–57. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin M, Morrison CD, Jones S, Mohamed N,
Bacher J and Plass C: Copy number gain and oncogenic activity of
YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J
Cancer. 125:603–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bajpai U, Sharma R, Kausar T, Dattagupta
S, Chattopadhayay TK and Ralhan R: Clinical significance of 14-3-3
zeta in human esophageal cancer. Int J Biol Markers. 23:231–237.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matta A, Siu KW and Ralhan R: 14-3-3 zeta
as novel molecular target for cancer therapy. Expert Opin Ther
Targets. 16:515–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Guo H, Treekitkarnmongkol W, Li P,
Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, et al: 14-3-3zeta
Cooperates with ErbB2 to promote ductal carcinoma in situ
progression to invasive breast cancer by inducing
epithelial-mesenchymal transition. Cancer Cell. 16:195–207. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J, Acharya S, Sahin O, Zhang Q, Saito
Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, et al: 14-3-3ζ turns
TGF-β's function from tumor suppressor to metastasis promoter in
breast cancer by contextual changes of Smad partners from p53 to
Gli2. Cancer Cell. 27:177–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cornell B and Toyo-Oka K: Deficiency of
14-3-3ε and 14-3-3ζ by the Wnt1 promoter-driven Cre recombinase
results in pigmentation defects. BMC Res Notes. 9:1802016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu J, Chen L, Chen Y, Hasan MK, Ghia EM,
Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, et al: Wnt5a
induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and
proliferation of chronic lymphocytic leukemia cells. Leukemia.
31:2608–2614. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang B, Shi Y, Gong A, Pan Z, Shi H, Yang
H, Fu H, Yan Y, Zhang X, Wang M, et al: HucMSC Exosome-delivered
14-3-3ζ orchestrates self-control of the Wnt response via
modulation of YAP during cutaneous regeneration. Stem Cells.
34:2485–2500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi JE, Hur W, Jung CK, Piao LS, Lyoo K,
Hong SW, Kim SW, Yoon HY and Yoon SK: Silencing of 14-3-3ζ
over-expression in hepatocellular carcinoma inhibits tumor growth
and enhances chemosensitivity to Cis-diammined dichloridoplatium.
Cancer Lett. 303:99–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davidson CE, Reese BE, Billingsley ML and
Yun JK: The protein stannin binds 14-3-3zeta and modulates
mitogen-activated protein kinase signaling. Brain Res Mol Brain
Res. 138:256–263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee YK, Hur W, Lee SW, Hong SW, Kim SW,
Choi JE and Yoon SK: Knockdown of 14-3-3ζ enhances radiosensitivity
and radio-induced apoptosis in CD133(+) liver cancer stem cells.
Exp Mol Med. 46:e772014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Shen H, Zhangyuan G, Huang R,
Zhang W, He Q, Jin K, Zhuo H, Zhang Z, Wang J, et al: 14-3-3ζ
delivered by hepatocellular carcinoma-derived exosomes impaired
anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death
Dis. 9:1592018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song J, Zhang X, Liao Z, Liang H, Chu L,
Dong W, Zhang X, Ge Q, Liu Q, Fan P, et al: 14-3-3ζ inhibits heme
oxygenase-1 (HO-1) degradation and promotes hepatocellular
carcinoma proliferation: Involvement of STAT3 signaling. J Exp Clin
Cancer Res. 38:32019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lian Q, Wang S, Zhang G, Wang D, Luo G,
Tang J, Chen L and Gu J: HCCDB: A database of hepatocellular
carcinoma expression atlas. Genomics Proteomics Bioinformatics.
16:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hutter C and Zenklusen JC: The cancer
genome atlas: Creating lasting value beyond its data. Cell.
173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
GTEx Consortium: The genotype-tissue
expression (GTEx) project. Nat Genet. 45:580–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altermann E and Klaenhammer TR:
PathwayVoyager: Pathway mapping using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database. BMC Genomics. 6:602005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 42015.doi: 10.7554/eLife.05005.
|
|
30
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th. New York:
Springer; 2017, View Article : Google Scholar
|
|
35
|
Pilati C, Letouze E, Nault JC, Imbeaud S,
Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette
G, et al: Genomic profiling of hepatocellular adenomas reveals
recurrent FRK-activating mutations and the mechanisms of malignant
transformation. Cancer Cell. 25:428–441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harding JJ, Nadakumar S, Armenia J, Khalil
DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, et
al: Prospective genotyping of hepatocellular carcinoma: Clinical
Implications of next-generation sequencing for matching patients to
targeted and immune therapies. Clin Cancer Res. 25:2116–2126. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM,
Sung CO, Baek D, Haq F, Ansari AA, Lee SY, et al: Genomic portrait
of resectable hepatocellular carcinomas: Implications of RB1and
FGF19 aberrations for patient stratifications. Hepatology.
60:1972–1982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schulze K, Imbeaud S, Letouze E,
Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C,
Shinde J, Soysouvanh F, et al: Exome sequencing of hepatocellular
carcinomas identifies new mutational signatures and potential
therapeutic targets. Nat Genet. 47:505–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fujimoto A, Totoku Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences of mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 7:760–764. 2012. View Article : Google Scholar
|
|
40
|
Hoadley KA, Yau C, Hinoue T, Wolf DM,
Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et
al: Cell-of-origin patterns dominate the molecular classification
of 10,000 tumors from 33 types of cancer. Cell. 173:291–304. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaplan A, Ottmann C and Fournier AE:
14-3-3 adaptor protein-protein interactions as therapeutic targets
for CNS diseases. Pharmacol Res. 125:114–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Woodcock JM, Goodwin KL, Sandow JJ, Coolen
C, Perugini MA, Webb AI, Pitson SM, Lopez AF and Carver JA: Role of
salt bridges in the dimer interface of 14-3-3ζ in dimer dynamics,
N-terminal α-helical order, and molecular chaperone activity. J
Biol Chem. 293:89–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Neal CL and Yu D: 14-3-3ζ as a prognostic
marker and therapeutic target for cancer. Expert Opin Ther Targets.
14:1343–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aghazadeh Y and Papadopoulos V: The role
of the 14-3-3 protein family in health, disease, and drug
development. Drug Discov Today. 21:278–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang Y, Lv P, Sun Z, Han L, Luo B and Zhou
W: 14-3-3ζ up-regulates hypoxia-inducible factor-1α in
hepatocellular carcinoma via activation of PI3K/Akt/NF-κB signal
transduction pathway. Int J Clin Exp Pathol. 8:15845–15853.
2015.PubMed/NCBI
|
|
46
|
Tang Y, Liu S, Li N, Guo W, Shi J, Yu H,
Zhang L, Wang K, Liu S and Cheng S: 14-3-3ζ promotes hepatocellular
carcinoma venous metastasis by modulating hypoxia-inducible
factor-1α. Oncotarget. 7:15854–15867. 2016.PubMed/NCBI
|
|
47
|
Tang Y, Zhang Y, Wang C, Sun Z, Li L, Dong
J and Zhou W: 14-3-3ζ binds to hepatitis B virus protein X and
maintains its protein stability in hepatocellular carcinoma cells.
Cancer Med. 7:5543–5553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tzivion G, Gupta VS, Kaplun L and Balan V:
14-3-3 proteins as potential oncogenes. Semin Cancer Biol.
16:203–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tang Y, Wang R, Zhang Y, Lin S, Qiao N,
Sun Z, Cheng S and Zhou W: Co-Upregulation of 14-3-3ζ and P-Akt is
associated with oncogenesis and recurrence of hepatocellular
carcinoma. Cell Physiol Biochem. 45:1097–1107. 2018. View Article : Google Scholar : PubMed/NCBI
|
